# Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

> **NCT01629875** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 268 (estimated)

## Conditions studied

- Moderate to Severe Glabellar Line

## Interventions

- **DRUG:** Generic equivalent of Clostridium Botulinum A Toxin
- **DRUG:** Botox (Clostridium Botulinum A Toxin)

## Key facts

- **NCT ID:** NCT01629875
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-11
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2012-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01629875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01629875, "Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01629875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*